From the beginning of the pandemic, ACE2 took center stage in the COVID-19 outbreak as a receptor for the spike glycoprotein of SARS-CoV-2 (Wrapp et al., 2020; Zhou et al., 2020), which spurred the development of vaccines and therapies targeting the ACE2-SARS-CoV-2 spike interaction. Here, ACE2 is linked to COVID-19.